• Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$3.20
+0 (0.00%)
Get New Renovacor Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RCOR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RCOR

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Renovacor in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $3.20.

This chart shows the closing price for RCOR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Renovacor. This rating has held steady since September 2023, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
8/2/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/29/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/28/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/23/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/21/2022Robert W. BairdDowngradeOutperform ➝ Neutral
9/20/2022Lifesci CapitalDowngradeOutperform ➝ Market Perform
9/20/2022BTIG ResearchDowngradeBuy ➝ Neutral
9/20/2022LADENBURG THALM/SH SHDowngradeBuy ➝ Neutral
9/14/2022BTIG ResearchInitiated CoverageBuy
9/12/2022Robert W. BairdInitiated CoverageOutperform
6/16/2022Lifesci CapitalReiterated RatingOutperform
5/13/2022Chardan CapitalReiterated RatingBuy$20.00
10/14/2021LADENBURG THALM/SH SHInitiated CoverageBuy$22.00
10/1/2021Chardan CapitalInitiated CoverageBuy$20.00
(Data available from 1/23/2020 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/27/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/23/2025

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Renovacor logo
Renovacor, Inc., a biotechnology company, focuses on delivering various precision therapies to enhance the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. It primarily focuses on the treatment of BCL2-associated athanogene 3 (BAG3) mutation-associated dilated cardiomyopathy (DCM). The company's lead product candidate is REN-001, a recombinant adeno-associated virus 9-based gene therapy designed to deliver a functional BAG3 gene to augment BAG3 protein levels in cardiomyocytes, and slow or halt progression of BAG3 DCM. It is also developing a pipeline of BAG3-associated gene therapies for diseases with high unmet medical need associated with mutations in the BAG3 gene and mechanistically linked to BAG3's expression and function. The company was founded in 2013 and is based in Greenwich, Connecticut.
Read More

Today's Range

Now: $3.20
Low: $3.20
High: $3.20

50 Day Range

MA: $3.07
Low: $2.56
High: $3.28

52 Week Range

Now: $3.20
Low: $1.34
High: $9.74

Volume

N/A

Average Volume

30,033 shs

Market Capitalization

$55.26 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Renovacor?

The following Wall Street sell-side analysts have issued research reports on Renovacor in the last twelve months:
View the latest analyst ratings for RCOR.

What is the current price target for Renovacor?

0 Wall Street analysts have set twelve-month price targets for Renovacor in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Renovacor in the next year.
View the latest price targets for RCOR.

What is the current consensus analyst rating for Renovacor?

Renovacor currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for RCOR.

What other companies compete with Renovacor?

How do I contact Renovacor's investor relations team?

Renovacor's physical mailing address is 17 STATE STREET 21 FLOOR, NEW YORK NY, 10004. The company's listed phone number is 610-424-2650 and its investor relations email address is investors@renovacor.com. The official website for Renovacor is renovacor.com. Learn More about contacing Renovacor investor relations.





Receive Renovacor News & Ratings Daily
Sign up to receive the latest news and ratings for Renovacor and its competitors with PriceTargets.com’s free daily newsletter.